Education
About Us
Working with TipRanks
Follow Us
Aridis Pharmaceuticals (ARDS)
:ARDS
Total Valuation
Aridis Pharmaceuticals has a market cap or net worth of $4.46K. The enterprise value is ―.
Market Cap$4.46K
Enterprise Value―
Share Statistics
Aridis Pharmaceuticals has 44,574,020 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding44,574,020
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Aridis Pharmaceuticals’s return on equity (ROE) is 1.27 and return on invested capital (ROIC) is 174.87%.
Return on Equity (ROE)1.27
Return on Assets (ROA)-2.09
Return on Invested Capital (ROIC)174.87%
Return on Capital Employed (ROCE)1.35
Revenue Per Employee0.00
Profits Per Employee-820.84K
Employee Count37
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Aridis Pharmaceuticals is -0.72. Aridis Pharmaceuticals’s PEG ratio is ―.
PE Ratio-0.72
PS Ratio0.00
PB Ratio>-0.01
Price to Fair Value-0.91
Price to FCF>-0.01
Price to Operating Cash Flow>-0.01
PEG Ratio―
Income Statement
In the last 12 months, Aridis Pharmaceuticals had revenue of 0.00 and earned -30.75M in profits. Earnings per share was -1.64.
Revenue0.00
Gross Profit0.00
Operating Income-29.99M
Pretax Income-30.37M
Net Income-30.75M
EBITDA-29.51M
Earnings Per Share (EPS)-1.64
Cash Flow
In the last 12 months, operating cash flow was -17.89M and capital expenditures -49.00K, giving a free cash flow of -17.93M billion.
Operating Cash Flow-17.89M
Free Cash Flow-17.93M
Free Cash Flow per Share-0.40
Dividends & Yields
Aridis Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta63.35
52-Week Price Change0.00%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)125.36K
Important Dates
Aridis Pharmaceuticals upcoming earnings date is May 20, 2025, TBA Not Confirmed.
Last Earnings DateNov 20, 2024
Next Earnings DateMay 20, 2025
Ex-Dividend Date―
Financial Position
Aridis Pharmaceuticals as a current ratio of 0.32, with Debt / Equity ratio of -25.30%
Current Ratio0.32
Quick Ratio0.32
Debt to Market Cap0.19
Net Debt to EBITDA-0.04
Interest Coverage Ratio-79.35
Taxes
In the past 12 months, Aridis Pharmaceuticals has paid 378.00K in taxes.
Income Tax378.00K
Effective Tax Rate-0.01
Enterprise Valuation
Aridis Pharmaceuticals EV to EBITDA ratio is -0.79, with an EV/FCF ratio of -0.80.
EV to Sales0.00
EV to EBITDA-0.79
EV to Free Cash Flow-0.80
EV to Operating Cash Flow-0.80
Balance Sheet
Aridis Pharmaceuticals has $35.00K in cash and marketable securities with $4.84M in debt, giving a net cash position of $4.80M billion.
Cash & Marketable Securities$35.00K
Total Debt$4.84M
Net Cash$4.80M
Net Cash Per Share$0.11
Tangible Book Value Per Share-$1.29
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Aridis Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―